906810-49-9

Usage

Uses

Used in Medicinal Chemistry:
(2S,5R)-tert-butyl 4-benzyl-2-ethyl-5-Methylpiperazine-1-carboxylate is used as a building block or intermediate in the synthesis of pharmaceutical compounds due to its unique structural features and stereochemistry. Its complex arrangement of functional groups can be exploited to create new drugs with specific therapeutic properties.
Used in Drug Design:
In the field of drug design, (2S,5R)-tert-butyl 4-benzyl-2-ethyl-5-Methylpiperazine-1-carboxylate serves as a valuable template for the development of novel therapeutic agents. Its distinct stereochemistry and functional groups can be utilized to design drugs with improved efficacy, selectivity, and reduced side effects.
Used in Chemical Research:
(2S,5R)-tert-butyl 4-benzyl-2-ethyl-5-Methylpiperazine-1-carboxylate is also used as a research tool in chemical studies, allowing scientists to explore the effects of stereochemistry on the properties and reactivity of molecules. This knowledge can be applied to the development of new synthetic methods and the understanding of molecular interactions in various chemical processes.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 906810-48-8 (3S,6R)-1-benzyl-3-ethyl-6-methyl-piperazine-2,5-dione 
• 906810-50-2 (2S,5R)-2-ethyl-4-benzyl-5-methyl-piperazine 

Relevant academic research and scientific papers

PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY

The present invention relates to novel processes for the preparation of the compound of the Formula A45: [Chemical formula should be inserted here as it appears in the paper abstract.] or a physiologically acceptable salt, solvate or prodrug thereof, whic

HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: Chemical formula should be inserted here as it appears on the abstract in paper form. or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

HETEROARYL SUBSTITUTED PYRAZINYL-PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having th